Vivoryon Therapeutics N.v. · EURONEXT:VVY
Vivoryon Therapeutics — FY2022 Earnings Presentation
11 slides from Vivoryon Therapeutics's earnings presentation, Apr 19, 2023
Slide 1: Full Year 2022 Results Webcast and Conference Call
FULL YEAR 2022 RESULTS WEBCAST AND CONFERENCE CALL April 19, 2023 |Vivoryon Therapeutics N.V.
Slide 2: Important notice and disclaimer
Important notice and disclaimer This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment
Slide 3: Lead Product Candidate: Varoglutamstat Prevents Formation of Toxic N3pE in AD
Lead Product Candidate: Varoglutamstat Prevents Formation of Toxic N3pE in AD DIFFERENTIATED APPROACH TO AD VAROGLUTAMSTAT TARGETS UPSTREAM PATHOGENESIS ◆ STATISTICALLY SIGNIFICANT changes in working Abeta CCL2 memory upregulated in AD ◆ CONVENIENT ADMINISTRATION with oral availability varoglutamsta
Slide 4: Varoglutamstat Clinical Development Strategy
Varoglutamstat Clinical Development Strategy Clear Path To Potential Regulatory Approval Based on Well-Informed, Extensive Phase 1 and Phase 2 Trials Pivotal study or Phase 2b VIVIAD Assessment of safety, tolerability and accelerated approval efficacy in 250 patients with MCI or FDA Fast Track desig
Slide 5: Clinical Portfolio Highlights
@Anca/Alex – updated for Stern comments, included cut off date as Clinical Portfolio Highlights footnote instead of completely deleting, Stern slide in backup as reference 2022 and Post-Period ◆ VIVIAD European Phase 2b study of varoglutamstat: on track for final data readout Q1/2024 ◆ Parallel grou
Slide 6: Corporate Development Highlights
@Anca/Alex – I tried to keep PhD / MD titled consistent from formatting Corporate Development Highlights perspective. I was not sure which was preferred, but this is now consistent with PR 2022 and Post-Period ◆ Financing events to support ongoing clinical development of varoglutamstat ◆ April 2022:
Slide 7: Condensed Statement Of Profit And Loss
Condensed Statement Of Profit And Loss In €k 2022 2021 % Gross profit - 9,196 Research and development expenses (20,224) (17,452) 16 % General and administrative expenses (8,908) (4,549) 96 % Operating loss (29,113) (12,798) 127 % Finance result 758 575 32 % Income taxes 199 (432) Net loss for perio
Slide 8: Key Financial Figures
Key Financial Figures In €k December 31, 2022 December 31, 2021 Cash and cash equivalents 26,555 14,661 Total assets 31,378 24,520 Total equity 26,506 16,557 Shares (number) 24,105,278 20,050,482 In €k December 31, 2022 December 31, 2021 Cash flows used in operating activities (21,794) (11,257) Cash
Slide 9: Positioned for Continued Value Generation
Positioned for Continued Value Generation Varoglutamstat: Differentiated Phase 2 Catalysts and Future Opportunities Asset with Unique Potential in AD ◆ UPCOMING CATALYSTS: ◆ STATISTICALLY SIGNIFICANT changes in working memory ◆ VIVIAD European Phase 2b: Final readout Q1/2024 ◆ CONVENIENT ADMINISTRAT
Slide 10: Q&A
Q&A
Slide 11: Vivoryon Therapeutics N.V
Vivoryon Therapeutics N.V Halle (Saale) Weinbergweg 22 06120 Halle (Saale) Germany Munich Franz-Josef-Delonge-Str. 5 81249 München Germany info@vivoryon.com +49 (0)345 555 99 00 www.vivoryon.com